Trilogy Global Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Trilogy Global Advisors’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-346,760	Closed	-$4.43M	–	85
2015 Q3	$4.43M	Sell	346,760 -122,585	-26%	-$1.52M	0.12%	74
2015 Q2	$5.19M	Sell	469,345 -398,405	-46%	-$4.4M	0.11%	81
2015 Q1	$9.91M	Sell	867,750 -409,285	-32%	-$4.34M	0.21%	73
2014 Q4	$12.9M	Sell	1,277,035 -495	-0%	-$5.21K	0.27%	73
2014 Q3	$13.4M	Sell	1,277,530 -447,370	-26%	-$4.21M	0.28%	73
2014 Q2	$14.9M	Buy	1,724,900 +5,500	+0.3%	+$46.3K	0.28%	78
2014 Q1	$15.1M	Sell	1,719,400 -543,560	-24%	-$4.73M	0.3%	80
2013 Q4	$18.6M	Buy	2,262,960 +508,540	+29%	+$4.03M	0.38%	74
2013 Q3	$13.3M	Buy	1,754,420 +136,250	+8%	+$991K	0.29%	75
2013 Q2	$12.2M	Buy	+1,618,170	New	+$11.8M	0.28%	74

Other funds holding RDY

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Trilogy Global Advisors's RDY Position: Q4 2015 in Review

Trilogy Global Advisors sold out of Dr. Reddy's Laboratories (RDY) in Q4 2015, closing a stake of 346,760 shares — an estimated $4.43M sold.

Trilogy Global Advisors first reported a position in RDY in Q2 2013 and held it in 10 quarters. The position peaked at $18.6M in Q4 2013. 174 funds tracked by Wall St. Rank hold RDY as of Q4 2015.

Trilogy Global Advisors reported no remaining Dr. Reddy's Laboratories position as of Q4 2015 after selling out during the quarter.
Trilogy Global Advisors sold 346,760 Dr. Reddy's Laboratories shares in Q4 2015, an estimated $4.43M.
Trilogy Global Advisors first reported a position in Dr. Reddy's Laboratories in Q2 2013 and held it in 10 quarters.
Trilogy Global Advisors's Dr. Reddy's Laboratories position peaked at $18.6M in Q4 2013.
174 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q4 2015.

Based on Trilogy Global Advisors's 13F filing for Q4 2015, filed 10 Feb 2016.